Quick Answer
Processa Pharmaceuticals, Inc. reported Cash And Cash Equivalents At Carrying Value of $5.54 million for the year ending 2025.
- Processa Pharmaceuticals, Inc. showed an increase of +364.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Processa Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), Processa Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 98.1%.
- Historical annual values: Fiscal year 2025: $5.54 million | Fiscal year 2024: $1.19 million | Fiscal year 2023: $4.71 million | Fiscal year 2022: $6.50 million | Fiscal year 2021: $16.50 million | Fiscal year 2020: $15.42 million | Fiscal year 2019: $691.5 thousand | Fiscal year 2018: $1.74 million | Fiscal year 2017: $2.85 million | Fiscal year 2016: $1.07 million | Fiscal year 2015: $2.1 thousand | Fiscal year 2014: $21.2 thousand | Fiscal year 2013: $186.9 thousand | Fiscal year 2012: $1.02 million | Fiscal year 2011: $2.79 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: